Related Experiment Video
Updated: Jun 3, 2026

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
Published on: September 12, 2016
Multi-omics analysis of immunologically relevant genes in multiple sclerosis to identify potential drug target
Wenhua Li1, Shuaishuai Chai2, Na Zhang1
1Department of Immunology, School of Basic Medicine, Tongji Medical College and State Key Laboratory for Diagnosis and Treatment of Severe Zoonotic Infectious Diseases, Huazhong University of Science and Technology, Wuhan 430030, China.
Background:
Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system characterized by demyelination and immune dysregulation. Despite the established link with immune function, the genetic and pathological mechanisms connecting immune-related genes to MS remain incompletely understood.
Methods:
We systematically integrated genome-wide association study (GWAS) data for various quantitative trait loci (QTLs) from public databases and literature, along with GWAS summary statistics for MS from IMSGC and FinnGen. Mendelian Randomization (MR) was used to infer potential causal relationships between immune-related factors and MS. To validate whether the same genetic variants underlie both traits, Bayesian colocalization analysis was performed. Summary-data-based Mendelian Randomization (SMR) further supported causality between the exposure and outcome. Finally, two-step MR was conducted to investigate whether immune cell subsets mediate the observed associations.
Results:
Fc receptor-like 3 (FCRL3) was identified as a protective factor for MS, supported by MR analyses at multiple levels: circulating protein (OR = 0.912, 95 % CI = 0.882-0.942), blood-derived gene expression (OR = 0.772, 95 % CI = 0.598-0.997), and cerebral cortex expression (OR = 0.573, 95 % CI = 0.455-0.721). Causality was further supported by SMR (pSMR = 5.38E-04; pHEIDI = 0.478) and Bayesian colocalization (PP.H₄ = 0.915). The protective effect of FCRL3 on MS was found to be partially mediated by CD3 expression on naïve CD4+ T cells.
Conclusion:
This study systematically evaluated the causal roles of immune-related genes in MS susceptibility and identified FCRL3 as a protective factor. These findings underscore the significance of FCRL3 in MS pathogenesis and suggest its potential as a target for future immunotherapeutic strategies.
Related Concept Videos
Therapeutic Drug Monitoring: Overview and Classification
Principles of Pharmacogenetics: Types of Genetic Variants
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Pharmacogenetics of Drug Metabolism: Overview
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Pharmacogenomics: Identification of New Drug Targets

